Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I get that feeling too. Would that be a good thing though?
Like clockwork...The MMs Shaking the tree after a huge run... Who got the 80s on the dip?
Institution investors will start coming maybe around 5... Then boom.
Churnnnnn!
I'm curious why it seems to not get as much coverage (which I like) as the other CA MJ producers. Whatever it is it has tempered volatility. But you think that this would be in the teens. In any case I want a slow steady climb.
Why do I get the feeling these guys are grooming the company to be bought by Big T&A or P
What assets or IP does Harvest Medicing have? Are they buying the patient base? Just curious.
Or both? Both are “viable.” The play on the producer sector in Canada is the way to go in general.
This could be. Canada green stocks are where the next boom will happen.
Just got in. 5000 @ .80
Yall just lost half your money. Another day on the pennies.
Sober analysis:
We see GeoVax as a risk reward opportunity with significant long term positive returns. Our price target of $0.25 represents a market cap of $12 million.
But risks must be taken into account when investors add positions.
One major risk is development/regulatory risk. We remind investors that GeoVax s HIV/AIDS vaccines are still in mid-stage development and the Company still needs to navigate through the regulatory process in the US and around the world, which proves to be long and tough. When it comes to HIV/AIDS vaccine, investors should be aware that this has been a tough area to tackle considering the failed developments already.
Cash burn is still a concern. Although most of GeoVax s clinical trials have been supported by the government grants, there is no guarantee that the Company will continue to get enough support to continue late stage clinical studies. In such a case, the Company needs alternative financing measures, which include equity or debt financing. We remind investors that equity financing will dilute existing shareholder base.
http://vaxess.com/wp-content/uploads/2016/01/the-most-influential-people-in-vaccines.pdf
#2 influential person in vaccines Dr. Thomas Monath.
https://www.geovax.com/scientific-advisory-board.html
https://eurekalert.org/pub_releases/2017-01/ehs-rds013117.php
Some insight into the technology behind their HIV vaccination.
That one share trade this morning. Pfft
Nice.
Comfortable is an overstatement. Let's say that there are legitimate routes to make money here. I assume you agree or why continue to watch and post?
Agreed. But having institutional investment can be seen in the 13g would allude that there is some legitimacy/interest to this company. This will run with Volume.
I'm in with 10k. I'm liking the numbers. Undervalued.
Has anyone received their settlement from the litigation on the Rosen vs Growlife case?
Double bottom?
The resistance isn't the issue it's the support that should concern. This hasn't really touched back at all. But I do hope it keeps rising.
Looks like some profit takers. Breaking this down.
Still got my 100k shares from .09.
Should I hold or sell? Hmm
Making so much money!!!!
Wow. Lovin this
Not that low. It looks like shaking out some hands here. Sell volume is mad low. And besides Amazon is down too.
Just wait till SINGLES DAY. Gonna outbeat last year.
They walking down to get in at the lows.
You're buggin. This thing is being upgraded. Testing lows around 101. P/E ratio is is great. Compared to competitors and buy sell ratio is optimistic. A lot of forward catalyst.